IP Library Granted Patent US 10,117,930
Granted Patent B2
US 10,117,930 · App. 13/265,252 · Granted Nov 6, 2018

Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder

Inventors: Yaron Ilan (Jerusalem, IL); Gadi Lalazar (Zion, IL); Tomer Adar (Modi'in, IL); Meir Mizrahi (Modi'in, IL); Ami Ben-Ya'acov (Jerusalem, IL)
Assignee: Immuron Limited
A61K39/39508C07K16/04C07K16/1232C07K16/26A61K2039/505A61K2039/507C07K2317/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,117,930
App. No.
13/265,252
Granted
Nov 6, 2018
Kind
B2
Abstract

The invention relates to the use of preparations enriched with anti LPS antibodies, such as those derived from mammalian colostrum or avian eggs, and optionally further antibodies against disease-associated antigens, colostrums, milk or milk product component/s and any adjuvants for treating, delaying or preventing the progression of a pathologic disorder such as chronic liver disease, cirrhosis and any complication or disorder associated therewith. The invention further relates to combined compositions comprising a combination of anti-LPS enriched antibody preparations and antibodies recognizing at least one antigen specific for a pathologic disorder and uses thereof in the treatment of immune-related disorders.

Claims (8)

1. A method of improving liver function in a subject with non alcoholic hepatic steatohepatitis (NASH), the method comprising:

selecting a subject who has NASH; and

orally administering to the selected subject a therapeutically effective dose of an anti-LPS enriched immunoglobulin preparation derived from colostrum, thereby improving liver function in the subject with NASH.

2. The method of claim 1 , comprising determining a level of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in the subject, and selecting a subject who has impaired liver function based on the level of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in the subject.

3. The method of claim 1 , further comprising determining a level of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in the subject, wherein a decrease in levels of AST or ALT indicates an improvement in liver function.

4. The method of claim 1 , wherein the colostrum is bovine colostrum.

5. The method of claim 1 , wherein the colostrum is freeze-dried colostrum.

6. The method of claim 5 , wherein the freeze-dried colostrum is in a tablet.

Assignments (2)
CHANGE OF NAME Recorded Dec 2, 2020
From: IMMURON LIMITED
To: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED
Reel/Frame 054519/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2011
From: ILAN, YARON; LALAZAR, GADI; ADAR, TOMER; MIZRAHI, MEIR; BEN-YA'ACOV, AMI; HADASSAH MEDICAL ORGANIZATION; HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD
To: IMMURON LIMITED
Reel/Frame 027445/0022 →
Continuity (2)
Provisional Application 61172922 · Apr 27, 2009
Related Publication 20120135007A1 · May 31, 2012